AstraZeneca PLC (AZNCF)
| Market Cap | 279.37B |
| Revenue (ttm) | 58.13B |
| Net Income (ttm) | 9.40B |
| Shares Out | n/a |
| EPS (ttm) | 6.02 |
| PE Ratio | 29.72 |
| Forward PE | n/a |
| Dividend | 3.13 (1.73%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 822 |
| Average Volume | 1,708 |
| Open | 179.60 |
| Previous Close | 179.10 |
| Day's Range | 179.60 - 181.92 |
| 52-Week Range | 122.26 - 188.50 |
| Beta | 0.17 |
| RSI | 57.04 |
| Earnings Date | Feb 10, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews
AstraZeneca: A Rare Compound Growth Opportunity In Biopharma
Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks
U.S. regulators are taking a fresh look at infant respiratory syncytial virus (RSV) antibody treatments after concerns raised by vaccine skeptics prompted Robert F. Kennedy Jr.'s health leadership tea...
AstraZeneca (AZN) Begins Phase 3 Trial of Enhertu for Ovarian Cancer
AstraZeneca (AZN) Begins Phase 3 Trial of Enhertu for Ovarian Cancer
Anglo American’s merger bonus was a pay wheeze too far | Nils Pratley
Miner will have to do things by the book after ditching plan to pay bosses millions in bonuses after Teck deal Anglo American drops plan to pay bosses millions in bonuses Shareholder rebellions over e...
BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025
Early data indicate that BI-1206 has the potential to reset one of the main resistance mechanisms to rituximab 47% of patients exhibited complete responses (CR), with an overall response rate of 80% F...
AstraZeneca (AZN) Price Target Raised by JPMorgan
AstraZeneca (AZN) Price Target Raised by JPMorgan
Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement
SAN FRANCISCO--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world's #1 CRM, today announced that AstraZeneca (LSE/STO/Nasdaq: AZN), a global, science-led biopharmaceutical company, has selected Agentf...
FDA Streamlines Clinical Study Requirements, Impacting AstraZeneca (AZN)
FDA Streamlines Clinical Study Requirements, Impacting AstraZeneca (AZN)
AstraZeneca (AZN) Could Benefit from FDA's Shift to Single Study Approval
AstraZeneca (AZN) Could Benefit from FDA's Shift to Single Study Approval
AstraZeneca (AZN) Set to Showcase Hematology Innovations at ASH 2025
AstraZeneca (AZN) Set to Showcase Hematology Innovations at ASH 2025
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine hematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) ...
AstraZeneca Shares Dip 0.7% Amid Patent Cliff Fears, But Pipeline Strength Fuels Long-Term Optimism
Thursday saw AstraZeneca PLC shares decline 0.7% and close at 13,546p as the pharmaceutical giant came to grips with new fears over impending patent expiries, despite the continued growth in revenues ...
AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report
The U.K. government is bringing together senior pharmaceutical executives to help chart a new direction for the country's drug-pricing system . Whitehall officials will invite reps from AstraZeneca Pl...
AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension
AstraZeneca's NDA for baxdrostat gains FDA priority review for treating hard-to-control hypertension. A decision is due in the second quarter of 2026.
AstraZeneca Hypertension Drug Baxdrostat Wins FDA Priority Review
(RTTNews) - AstraZeneca's (AZN) New Drug Application (NDA) for experimental hypertension drug baxdrostat has been granted Priority Review by the U.S. Food and Drug Administration.
UK Government Partners with AstraZeneca (AZN) for Drug Pricing Strategy
UK Government Partners with AstraZeneca (AZN) for Drug Pricing Strategy
AstraZeneca (AZN) Gains FDA Priority Review for Hypertension Drug
AstraZeneca (AZN) Gains FDA Priority Review for Hypertension Drug
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatmen...
Potential Vaccine Schedule Revisions Could Impact AstraZeneca (AZN)
Potential Vaccine Schedule Revisions Could Impact AstraZeneca (AZN)
Michael Hakes' Past Picks: Aritzia, Airbus & AstraZeneca
Michael Hakes, senior portfolio manager at Murray Wealth Group, discusses his past stock picks and how they're doing in the market today.
BREAKING: Trump strikes major deal with UK on drug pricing
FOX Business White House correspondent Edward Lawrence reports the details of President Donald Trump's pharmaceutical deal with the U.K. on 'Varney & Co.'
U.S.-U.K. Pharmaceutical Pricing Agreement to Benefit AstraZeneca (AZN)
U.S.-U.K. Pharmaceutical Pricing Agreement to Benefit AstraZeneca (AZN)
UK Nears Pharmaceuticals Deal with US Benefiting AstraZeneca (AZN)
UK Nears Pharmaceuticals Deal with US Benefiting AstraZeneca (AZN)
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AstraZeneca Shares Soar 7% as Pharma Giant Unveils Breakthrough Cancer Drug Data
Anglo-Swedish pharmaceutical giant AstraZeneca has made investors jump with record-breaking trial outcomes of its next-generation lung cancer treatment, and its shares shot up by 7% on the London Stoc...